Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.
Abstract
High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.
참고문헌 (15)
- Biswal BK, "Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells", J Biochem, 146, pp.693~703 (2009)
- Widemann BC, "Understanding and managing methotrexate nephrotoxicity", Oncologist, 11, pp.694~703 (2006)
- Relling MV, "Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion", Cancer, 62, pp.884~888 (1988)
- Widemann BC, "Carboxypeptidase- G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity", Cancer, 76, pp.521~526 (1995)
- Lawrenz-Wolf B, "Severe renal impairment of methotrexate elimination after high dose therapy", Klin Padiatr, 206, pp.319~326 (1994)
- Relling MV, "Patient characteristics associated with high-risk methotrexate concentrations and toxicity", J Clin Oncol, 12, pp.1667~1672 (1994)
- Cassano WF, "Serious methotrexate toxicity caused by interaction with ibuprofen", Am J Pediatr Hematol Oncol, 11, pp.481~482 (1989)
- Delepine N, "Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma", Anticancer Res, 15, pp.489~494 (1995)
- Bleyer WA, "The clinical pharmacology of methotrexate: new applications of an old drug", Cancer, 41, pp.36~51 (1978)
- Abelson HT, "Methotrexate- induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine", J Clin Oncol, 1, pp.208~216 (1983)
- J Clin Oncol, "Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction", J Clin Oncol, 15, pp.2125~2134 (1997)
- Meyers PA, "Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience", J Clin Oncol, 10, pp.5~15 (1992)
- Wall SM, "Effective clearance of methotrexate using high-flux hemodialysis membranes", Am J Kidney Dis, 28, pp.846~854 (1996)
- Djerassi I, "Removal of methotrexate by filtration-adsorption using charcoal filters or by hemodialysis", Cancer Treat Rep, 61, pp.751~752 (1977)
- Saland JM, "Effective removal of methotrexate by high-flux hemodialysis", Pediatr Nephrol, 17, pp.825~829 (2002)